Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
In November 2022, Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and planned to engage an investment bank to act as a strategic advisor. But the battered company failed to find any alternatives, and the company's board approved a plan of liquidation and dissolution. The biotech said its board approved the plan with a special meeting of Rubius' stockholders being lined up to seek a green light, per an SEC filing. The biotech terminated its
Pablo Cagnoni, who was CEO of the soon-to-shutter Rubius Therapeutics Inc. until earlier this year, has joined another Flagship Pioneering-backed startup.
Rubius Therapeutics is in the final days of its existence. The company is laying off 82% of its workforce and will begin looking at a sale or merger.
Rubius Therapeutics Inc (NASDAQ: RUBY) initiated a process to explore a range of strategic alternatives and plans to engage an investment bank to act as a strategic advisor for this process. In September, Rubius announced plans to restructure and align resources extending the company's cash runway until the end of 2023. As a result of this process, Rubius is reducing its workforce by 84% and will retain certain employees to execute the process. The company also appointed Dannielle Appelhans as p
Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to ma
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT. A live aud
Red blood cell medicines company Rubius Therapeutics Inc. is laying off 160 people — 75% of its staff — as it throws out its platform and begins anew. Cambridge-based Rubius (Nasdaq: RUBY) said in a press release Tuesday that it would discontinue work on nearly all of its existing programs as it scraps its existing platform in favor of a new, "next generation red blood cell platform." Rubius had been testing two drugs in solid-tumor cancers, which were in Phase 1 trials.
Rubius Therapeutics Inc (NASDAQ: RUBY) announced plans to restructure and align resources to advance its next-generation red blood cell-based cell conjugation platform. The company said that with over 80 patients dosed across three clinical trials, Rubius Therapeutics has demonstrated that engineered red blood cells can be manufactured at scale, safely administered, and activate a patient's immune system, resulting in clinical benefits in certain cancer patients. To enable continued investment i
Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid Tumors Investor Teleconference and Webcast Scheduled Today at 7:30 a.m. EDT CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing a
Investor Teleconference and Webcast Scheduled Tomorrow, September 13, 2022, at 7:30 a.m. EDTCAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the Company plans to provide a strategic update and host an inv